ResearchScenic Biotech joins Michael J. Fox LRRK2 consortium with a novel lysosomal bet on Parkinson’sScenic Biotech has joined the Michael J. Fox Foundation’s LRRK2 consortium to test a Parkinson’s disease approach that targets neither LRRK2 nor GCase directly. more ➔
clinical dataSanofi’s $11.6bn Bioverativ purchase looks hit-and miss after phase 3 rare diseases drug runs into troubleSanofi’s $11.6bn Bioverativ acquisition is back under scrutiny after riliprubart, a rare disease drug inherited through the deal, failed a phase 3 CIDP study. While Altuviiio has become a blockbuster, … more ➔
fundraisingCircio completes NOK300m financing to fund circular RNA platform developmentOslo-based Circio has completed a NOK300m (€27m) financing round, extending its runway to the end of 2030 and giving the company funds to advance its circVec circular RNA expression platform toward … more ➔
licensingAlzeCure shares soar over 300% after Eli Lilly strikes Alzheimer’s deal worth over $1bnSwedish biotech AlzeCure Pharma entered a collaboration and licensing agreement with Eli Lilly, granting the biopharma giant global rights to its Alzheimer’s disease candidate Alzstatin (ACD680). Under … more ➔
obesityBoehringer/Zealand obesity drug delivers Phase III weight loss, but side effects raise questionsBoehringer Ingelheim has reported new Phase III data for survodutide, its once-weekly dual GLP-1/glucagon receptor agonist for obesity, highlighting reductions in body weight, visceral fat and liver … more ➔
clinical dataBial drops pariceract after Phase IIb failure in GBA-associated Parkinson’sPortuguese drugmaker BIAL has discontinued development of BIA 28-6156, also known as pariceract, after a Phase IIb study failed to show that the oral therapy could slow progression in patients with GBA-associated … more ➔
EngitixlicensingGSK taps Engitix’s platform in liver fibrosis deal worth up to £44.5m upfrontLondon-based Engitix Ltd has entered a strategic research collaboration and option agreement with GSK to discover and validate new therapeutic targets for liver fibrosis regression, adding another pharma … more ➔
licensingRoche bets on BTK degradation in $2.3bn Nurix dealSwiss pharma giant Roche has signed a global licensing and collaboration agreement with US biotech Nurix Therapeutics to co-develop and co-commercialise bexobrutideg, an oral Bruton’s tyrosine kinase … more ➔
clinical dataADC Therapeutics stock halves after Zynlonta Phase III records three times more deaths than control armSwiss ADC specialist ADC Therapeutics has reported a statistically positive Phase III result for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma, but a higher rate of fatal adverse events … more ➔
InvestmentLilly and Boehringer pause $2bn German investments over planned drug-spending curbsThe announcements came almost simultaneously and send a clear signal to policymakers and the industry: both US pharmaceutical group Eli Lilly and German-based Boehringer Ingelheim are calling planned … more ➔
Engitix
